Understanding Osmotic Demyelination Syndrome
Osmotic demyelination syndrome (ODS), also called central pontine myelinolysis (CPM) and extra-pontine myelinolysis (EPM), is a demyelination of the pons region of the central nervous system that interrupts the flow of information within the brain and body.
Demyelination:Destruction of myelin, the insulating layer around axons, essential for the proper functioning of the nervous system.
ODS is most often derived as a complication of treatment of patients with hypontremia (low serum sodium).
Correcting for hyponatremia too rapidly in the hospital can lead to:
Acute damage of the myelin sheath in the pons area of the brain
Patient care is primarily supportive only
Serious long-term (chronic) disability and potentially death
There is no cure or specific treatment currently available
Clinical Signs and Symptoms
ODS is first diagnosed clinically and confirmed by MRI. However, it often takes days to several weeks after acute symptoms occur for confirmation of demyelination of the pons to be detected by MRI.
Difficulty swallowing and / or speaking
Confusion, delirium, hallucinations
Balance problems, tremors
Reduced alertness, drowsiness, poor responses
Patients who develop ODS require long-term supportive care
There is no known cure or specific treatment
ENDECE Approach To Remyelination
ENDECE has discovered and is developing NDC-1308, a new therapy with a dual mechanism of action (MOA) designed to provide the necessary anti-inflammatory, pro-repair environment at lesions and upregulate genes necessary for inducing OPCs to differentiate into mature oligodendrocytes responsible for remyelination.
For more information go to About NDC-1308
To learn more go to:
A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome.
To request more information go to; ENDECE.com/contact